The circulating sVAP-1 level is associated with disease severity and could be used to predict the presence of significant fibrosis in NASH, suggesting that sVAP-1 alone or in combination with other potential fibrosis markers could be used as biomarkers for NASH disease progression (Kurkijärvi et al., 1998; Weston and Adams, 2011). This evidence concerns the gene SNAP47 and metabolic dysfunction-associated steatohepatitis.